Compare PDYN & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | TTRX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | 70 | 2 |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.2M | 281.2M |
| IPO Year | N/A | N/A |
| Metric | PDYN | TTRX |
|---|---|---|
| Price | $5.30 | $9.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.67 | $8.00 |
| AVG Volume (30 Days) | ★ 2.3M | 86.0K |
| Earning Date | 05-05-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $384.48 | N/A |
| Revenue Next Year | $63.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.14 | $2.57 |
| 52 Week High | $12.79 | $11.69 |
| Indicator | PDYN | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 72.73 |
| Support Level | $5.04 | $4.40 |
| Resistance Level | $6.71 | N/A |
| Average True Range (ATR) | 0.48 | 0.99 |
| MACD | -0.07 | 0.24 |
| Stochastic Oscillator | 4.38 | 63.82 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.